Skip to content

Efficacy of erythromycin cycloester combined with azithromycin in the treatment of severe mycoplasma pneumonia and its effect on cytokines.

A randomized controlled clinical trial of erythromycin cyclic ester combined with azithromycin in the treatment of severe mycoplasma pneumonia and its effect on cytokines

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055258
Enrollment
Unknown
Registered
2022-01-05
Start date
2021-02-08
Completion date
Unknown
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe mycoplasma pneumoniae pneumonia

Interventions

Test group:The experimental group used cyclic ester erythromycin combined with azithromycin to treat SMPP
control group:Treatment of SMPP with azithromycin

Sponsors

Maternity and Child Health Hospital of Hubei Province
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Based on the diagnosis of MPP, any 2 of the first 3 and (or) any 1 of the last 2 of the following criteria are used as the diagnostic criteria for SMPP: 1. Obvious shortness of breath or tachycardia (= 50 beats/minute, heart rate >= 150 beats/minute; 1-5 years old, breathing >= 40 beats/minute, heart rate >= 140 beats/minute; > 5 years old, breathing >= 30 beats/minute, heart rate >= 120 beats/minute), With or without a decrease in arterial blood pressure (systolic blood pressure = 38.5? or lung imaging does not improve or even progress), or the fever lasts for more than 10 days; 3. The chest imaging shows large patches of shadows , Occupying a lung segment or above the lung lobe, can involve single or multi-lobe lesions; 4. Pulmonary complications such as pleural effusion, atelectasis, necrotizing pneumonia/pulmonary abscess, etc.; 5. Severe hypoxemia (PaO2 < 60mmHg) or combined with serious damage to other functions (central nervous system infection, heart failure, myocarditis, gastrointestinal bleeding, obvious electrolyte/acid-base balance disorder, etc.).

Exclusion criteria

Exclusion criteria: 1.Infectious diseases of other systems (such as cardiovascular, nervous, urinary, digestive system, etc.), and pneumonia as co-infected; 2.Patients who are allergic or allergic to the drugs in this study; 3.Congenital immunodeficiency; 4.Recently Those who use other medications.

Design outcomes

Primary

MeasureTime frame
CRP;LDH;ESR;HGF;TNF-a;IL-4;IL-6;IL-10;

Countries

China

Contacts

Public ContactYue Jing

Maternity and Child Health Hospital of Hubei Province

657057316@qq.com+86 15807195362

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026